Improving risk prediction in hypertrophic cardiomyopathy: the key role of Dutch founder variants R. WalshY. M. Pinto Editor’s Comment Open access 10 May 2021 Pages: 299 - 300
Risk stratification and subclinical phenotyping of dilated and/or arrhythmogenic cardiomyopathy mutation-positive relatives: CVON eDETECT consortium R. W. RoudijkK. TahaF. W. Asselbergs Point of View Open access 02 February 2021 Pages: 301 - 308
Chest pain triage: gut feeling or protocol-based care? R. T. A. WillemsenA. W. J. van ’t Hof Commentary Open access 10 May 2021 Pages: 309 - 310
The first multicentre study on coronary anomalies in the Netherlands: MuSCAT C. J. KoppelB. W. DriesenH. W. Vliegen Original Article – Study Design Article Open access 08 March 2021 Pages: 311 - 317
BIO FOr CARE: biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variants—design and status M. JansenI. ChristiaansA. F. Baas Original Article – Study Design Article Open access 02 February 2021 Pages: 318 - 329
Sonothrombolysis in the ambulance for ST-elevation myocardial infarction: rationale and protocol S. El KadiT. R. PorterO. Kamp Original Article – Study Design Article Open access 12 November 2020 Pages: 330 - 337
Performance of a simplified HEART score and HEART-GP score for evaluating chest pain in urgent primary care R. E. HarskampM. KletonW. A. M. Lucassen Original Article Open access 06 January 2021 Pages: 338 - 347
Sharing primary percutaneous coronary intervention care: first experiences with South Limburg ST-elevation myocardial infarction network A. LuxJ. VainerSouth Limburg Interventional Cardiology Group, the Netherlands Original Article Open access 03 February 2021 Pages: 348 - 353
Effect of cardiac resynchronisation therapy in dilated cardiomyopathy S. BouwmeesterL. X. van Nunen Heart Beat Open access 23 February 2021 Pages: 354 - 355
